Cytokinetics Q3 net loss $306M; aficamten PDUFA on track; raises $750M convertible notes

CYTOKINETICS INC

2025-Q3 EPS reported -$5.04 revenue$70,284,000

Q3 net loss $306.2M ($2.55/share) vs $160.5M loss in prior year; includes $121.2M debt conversion expense.
Cash, cash equivalents & investments $1.25B at Sep 30; raised $750M 1.75% convertible notes due 2031, used $402.5M to retire $399.5M of 2027 notes.
PDUFA date for aficamten NDA remains Dec 26, 2025; commercial launch preparations on track.
Updated FY2025 GAAP operating expense guidance to $680M-$700M (prior $670M-$710M).
Total Q3 revenue $1.9M (vs $0.5M); R&D $99.2M, G&A $69.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.